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Abstract
Despite inflammatory and immune mechanisms participating to atherogenesis and dendritic cells (DCs) driving immune
and non-immune tissue injury response, the interactions between DCs and vascular smooth muscle cells (VSMCs) possibly
relevant to vascular pathology including atherogenesis are still unclear. To address this issue, immature DCs (iDCs)
generated from CD14+ cells isolated from healthy donors were matured either with cytokines (mDCs), or co-cultured (ccDCs)
with human coronary artery VSMCs (CASMCs) using transwell chambers. Co-culture induced DC immunophenotypical and
functional maturation similar to cytokines, as demonstrated by flow cytometry and mixed lymphocyte reaction. In turn,
factors from mDCs and ccDCs induced CASMC migration. MCP-1 and TNFa, secreted from DCs, and IL-6 and MCP-1, secreted
from CASMCs, were primarily involved. mDCs adhesion to CASMCs was enhanced by CASMC pre-treatment with IFNc and
TNFa ICAM-1 and VCAM-1 were involved, since the expression of specific mRNAs for these molecules increased and
adhesion was inhibited by neutralizing antibodies to the counter-receptors CD11c and CD18. Adhesion was also inhibited
by CASMC pre-treatment with the HMG-CoA-reductase inhibitor atorvastatin and the PPARc agonist rosiglitazone, which
suggests a further mechanism for the anti-inflammatory action of these drugs. Adhesion of DCs to VSMCs was shown also in
vivo in rat carotid 7 to 21 days after crush and incision injury. The findings indicate that DCs and VSMCs can interact with
reciprocal stimulation, possibly leading to perpetuate inflammation and vascular wall remodelling, and that the interaction
is enhanced by a cytokine-rich inflammatory environment and down-regulated by HMGCoA-reductase inhibitors and PPARc
agonists.
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Introduction
Inflammatory mechanisms play a key pathogenic role in arterial
wall remodelling in response to different types of injury - including
atherosclerosis, occasional or surgical trauma and arteritis [1–3] -
and may lead to worsening and complication of disease [1,4]. The
geometry of the process, whether involving the whole circumfer-
ence of the vessel or only part of it and where and how far along
the vessel axis, depends primarily on the type of injury or
dysregulation of the underlying mechanisms. The secretion of pro-
inflammatory factors and direct intercellular interaction both
cooperate to drive the process, but the regulatory pathways are not
yet understood in detail.
A consequence of inflammation in the arterial wall is
hypertrophy of intimal tissue, leading to wall thickening and
eventually to stenosis of the lumen [3,5]. The onset and
progression of this process include functional changes in endothe-
lial cells, T lymphocytes, monocyte-derived macrophages and
vascular smooth muscle cells (VSMCs) [1,2,5]. Activation of all
these cells leads to the generation of a wide spectrum of hydrolases,
cytokines, chemokines, adhesion molecules and growth factors,
together with lipid accumulation and proliferation of VSMCs and
fibroblasts [1]. Immunohistochemical studies have revealed
mononuclear cell infiltration and accumulation of activated T
cells in early and late atherosclerotic lesions [6]. In these
conditions, VSMCs are stimulated and show altered expression
of transcription factors, growth factors, apoptosis-regulating genes,
integrins, proteases and extracellular matrix proteins. They
acquire increased capacity to proliferate, migrate, and secrete
great amounts of extracellular matrix proteins [7].
Dendritic cells (DCs), the professional antigen presenting cells of
the immune system, are candidate to a major role in the onset and
progression of inflammation, even independent of specific immune
responses. They are present in the normal human arterial intima
and adventitia as part of vascular-associated lymphoid tissue
(VALT), consisting of accumulations of immunocompetent and
antigen presenting cells, which screen the microenvironment for
potentially harmful antigens and drive inflammatory responses [8].
Many DCs localize to the neointima of atherosclerotic lesions
together with T-lymphocytes, NK cells, mast cells and neointimal
VSMCs [6,8,9–11]. Dendritic cells have not yet been found in
normal arteries of laboratory rodents, but appear in response to
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atherogenic stimuli [12] and traumatic injury [2,13,14]. Endothe-
lial dysfunction stimulates DC migration and adhesion [15] and
the same occurs upon increased vascular oxidative stress [16].
The response of vascular smooth muscle cells to the inflamma-
tory microenvironment of diseased arteries has been the object of
several studies. Notwithstanding, the possible role of VSMCs in
retaining and activating DCs in atherosclerotic lesions and,
reciprocally, that of DCs in activating VSMCs to the altered
functional state characteristic of those lesions are still unclear. This
study was aimed at investigating the interaction of human
coronary smooth muscle cells and human DCs in vitro and the
possible influence of an inflammatory environment on this
interaction. Since intercellular adhesion was a key result, we also
addressed whether this finding could be replicated in vivo, in an
experimental model of vascular wall inflammation in the rat.
Methods
This study was approved by the Institutional Ethical Committee
of the Azienda Ospedaliero-Universitaria Careggi, Firenze (prot.
N. 2011/0034455 rif. N. 15/11); written informed consent was
obtained by healthy donors.
Coronary artery smooth muscle cell culture
Human coronary artery smooth muscle cells (CASMCs, lots
0000184180 and 0000169150) were purchased from Lonza
(Walkersville, MD) which characterized them by positive immu-
nostaining for alpha-smooth muscle actin (a-SMA) and negative
immunostaining for factor VIII. Cells were grown in smooth
muscle basal medium (SmBM) supplemented with hEGF, insulin,
hFGF-B and gentamin/amphotericin-B (SmGM-2 SingleQuots;
Lonza), 5% (v/v) heat inactivated fetal bovine serum (Hyclone
Defined FBS; Thermo Ficher Scientific, Waltman, MA), 100 U/
mL penicillin, 100 mg/mL streptomycin and 2 mmol/L glutamine
(Sigma-Aldrich, St Louis, MO, USA), in a humidified atmosphere
with 5% CO2 in air. Culture medium was changed every 2 days.
Experiments were performed using cells between the 5th and 10th
passage.
Generation and maturation of DCs
Following a previously published method [17], mononuclear
cells were isolated by Ficoll/Paque density gradient centrifugation
from buffy coats obtained from healthy donors; written informed
consent was obtained upon approval by the local Ethical
Committee (prot. N. 2011/0034455 rif. N. 15/11). Micromag-
netic-selected CD14+ cells were cultured in RPMI-1640 with
1000 U/mL rGM-CSF (Leucomax; Sandoz-Wander Pharma,
Bern, CH) and 1000 U/mL IL-4 (R&D System, Minneapolis,
MN, USA) for 6 days to generate immature DCs (iDCs). On day
7, non-adherent cells were harvested and analysed by flow
cytometry technique (FACScanto; BD Biosciences, Bedford,
MA, USA). To induce maturation, iDCs were stimulated with
10 ng/mL TNFa, 1000 U/mL IL-6 and 10 ng/mL IL1-b for
24 h and the resulting mature DCs (mDCs) were analysed by flow
cytometry. The following fluorescent monoclonal antibodies were
used for flow cytometry analysis of iDCs and mDCs: CD80-
phycoerythtrin (PE), CD86-fluorescein isothiocyanate (FITC),
CD86-allophycocyanin (APC; for blocking experiments), CD83-
PE, DC-SIGN-PE, HLA-DR-FITC, CD38-PE, CCR-7-FITC
(BD Pharmingen; San Diego, CA). In order to block Fc-mediated
unspecific binding, cells were pre-incubated with serum and PBS
(1:1) for 30 min at 4uC. Isotype-matched antibodies were used as
negative control. 7-amino-actinomycin D (7-AAD; Sigma-Aldrich,
St Louis, Mo, USA) was used to exclude dead cells from analysis.
Co-culture of CASMCs and iDCs
Immature DCs (iDCs) derived from CD14+ cells and CASMCs
were co-cultured for 36 h in RPMI with 10% Hyclone Defined
FBS (Thermo Fisher Scientific) without the maturation cocktail. In
detail, in order to address the role of soluble factors released by the
co-culture, CASMCs were plated in 6 multiwells, in which
transwell chambers with 0.4 mm pore sized membranes were
added (Millicell inserts; Merk-Millipore, Darmstadt, Germany).
Immature DCs were plated into transwell chamber, in order to
avoid any direct contact between the two types of cells while
allowing medium sharing. After 36 h of co-culture in air with 5%
CO2 at 37uC, DCs were collected and analysed by flow cytometry
and mixed lymphocyte reaction (MLR). In some experiments
CASMCs were treated for 24 h with inflammatory cytokines, i.e.
50 ng/mL TNFa (R&D System) and 50 ng/mL IFNc (Peprotech,
London, UK) before co-culturing with DCs. In the blocking
experiments, co-cultures of iDCs and CASMCs were set up in the
presence of neutralizing monoclonal antibodies against IL-6
(Merk-Millipore), TNFa and MCP-1 (R&D Systems). Mouse
monoclonal IgG2b and IgG1 negative controls were from Merk-
Millipore.
Co-cultures were also set up in serum-free medium, in order to
exclude any confounding factors contained in the serum during
DC maturation. Briefly, monocyte-derived immature DCs (iDCs)
were co-cultured with CASMCs, inside transwell chambers, in
RPMI with or without FBS. Obtained DCs were analysed by flow
cytometry.
Animal studies
The investigation conformed with the Guide for the Care and Use of
Laboratory Animals (NIH Publication No. 85-23, revised 1996) and
with the Italian (D.L. 116/92) and European Community
(Directive 86/609/EEC, in OJ L 358 of December 18, 1986)
guidelines on the use and protection of animals in experimental
research. The study was approved by Ethical Committee For
Animal Research of the Department of Pharmaceutical and
Biomedical Sciences, University of Salerno, in Fisciano, SA, Italy
on 8th September 2011. Adult male Wistar rats (200–250 g) were
obtained from Harlan Italy (San Pietro al Natisone, Udine, Italy).
All rats were acclimated in individual cages for 1 week before
experimentation and appeared healthy at visual inspection. They
were maintained on a 12 h light/dark cycle at 24uC, at a relative
humidity of 60%, and received food and water ad libitum. They
were anaesthetized for surgery and for sacrifice by intraperitoneal
injection of ketamine hydrochloride (80 mg/kg). Following a
procedure described in detail elsewhere [18] the rats (three for
each time point) were anesthetized and given an intravenous dose
of ticarcillin (50 mg/kg). Through an incision in the anterior neck
region a plastic Scanlan clamp for coronary artery bypass grafting
was applied on a carotid for 10 s and a full thickness, 0.5 mm
longitudinal incision was made through the carotid wall.
Haemostasis was obtained with a single adventitial 8.0-gauge
polypropylene stick. The other carotid was left uninjured, as
control. Injured and uninjured carotids, 7, 14 and 21 days after
injury, were analysed from three rats for each time point; three
uninjured rats were used as further controls. Each animal
represents an experimental unit.
Isolation of human lymphocytes and mixed lymphocyte
reaction (MLR)
Allogeneic peripheral blood mononuclear cells were seeded in
RPMI 1640 and 10% FBS and monocytes were let to adhere.
Leukocytes remained in suspension were collected, centrifuged at
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1200 rpm for 10 min and used for MLR, as previously published
[19]. Briefly, lymphocytes were seeded into 96-well plates at 105
cells/well and purified allogeneic DCs (56103) were added to each
well and incubated for 5 days at 37uC in a humidified chamber in
air and 5% CO2. For the last 18 h, 1 mCi of [methyl-
3H]thymi-
dine (Amersham Pharmacia Biotech, Little Chalfont, UK) was
added to each well. Cells were finally collected by a Filtermate Cell
Harvester (Perkin–Elmer, Waltham, MA, USA). 3H-Thymidine
uptake was quantified by liquid scintillation counting on a
TopCount NXT Microplate Scintillation Counter (Perkin–Elmer).
Each experiment was performed in triplicate.
Electron microscopy
Cells in single culture were fixed upon suspension in medium.
Co-cultures of DCs adhering to CASMCs were fixed, then
removed with a scraper and pelletted. Rat carotids were fixed by
immersion. All samples were fixed in 2% formaldehyde and 2.5%
glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, osmicated and
embedded in epoxy resin. Sections were stained with lead acetate
and uranyl acetate and observed in a Jeol JEM 1010 electron
microscope (Tokyo, Japan), at 80 kV, to assess the presence,
localization and reciprocal contacts of VSMC and DCs.
Immunohistochemistry
Cytospins of iDCs and mDCs were fixed with acetone for 5 min
at room temperature. After blocking non-specific binding sites
with 10 ng/mL bovine serum albumin (Sigma-Aldrich) in 0.1 M
phosphate-buffer, pH 7.4, the slides were tagged with primary
antibodies against CD207/langerin (IgG2b, clone 12D6; Novo-
castra Laboratories, Newcastle, UK), 1:100, and DC-SIGN
(polyclonal; Sigma-Aldrich), 1:50, overnight at room temperature,
followed by FITC-labelled, goat anti-mouse or anti-rabbit,
polyclonal antibodies (Sigma-Aldrich), 1:50, for 60 minutes at
37uC. Omission of primary antibodies or substitution with
irrelevant ones were used as negative controls. Skin sections
including epidermis (containing langerin positive, DC-SIGN
negative Langerhans cells) and dermis (containing langerin
negative, DC-SIGN positive connective tissue dendritic cells) were
used as positive controls. The slides were mounted with Gel/
Mount (Biomeda, Foster City, CA, USA), observed in an Axioskop
microscope equipped for epifluorescence (Zeiss, Oberkochen,
Germany) and photographed with an Axio Vision 4 system with
a digital multichannel fluorescence module and dedicated software
(Zeiss).
For a-SMA detection in CASMCs, cells grown on coverslips
were fixed with 2% phosphate-buffered formaldehyde and labeled
with anti–human a-SMA monoclonal antibody (1:50, Dako A/S,
Denmark), overnight at 4uC, followed by an Alexa Fluor 594
conjugated goat-anti mouse secondary antibody (1:250, Molecular
Probes, Oregon, USA), for 1 h at room temperature. CASMCs
expressed a-SMA as expected from Lonza indications (not shown).
Real- time PCR
Cells were seeded at 80% confluence onto 6 cm-diameter Petri
dishes in SmBM medium supplemented with cytokines, growth-
factors and 5% (v/v) FBS, starved for 24 h (using only medium
and 0.1% FBS) and then stimulated for 24 h with TNFa or IFNc
(50 ng/mL either cytokine). Total RNA was extracted using TRI-
reagent (Sigma-Aldrich) according to manufacturer’s instructions
and 1 mg of total RNA was reverse transcribed using Stratagene kit
(Quiagen, Venlo, Netherlands) and random primers. Quantitative
real-time PCR was performed by incubating sample cDNA or
control cDNA in triplicate with Sybr Green PCR Master MIX
(Superarray Bioscience, Frederick, MD, USA) and primers specific
for genes to be tested and for GAPDH as housekeeping gene in 96
well-microtiter plates. ICAM-1, VCAM-1 and GAPDH-specific
primers (Table 1) were obtained by Life Technologies (Carlsbed,
CA, USA). PCR was performed on an ABI PRISM 7900 (Applied
Biosystems, Termo Fisher Scientific) as follows: 50uC for 2 min,
95uC for 10 min followed by 40 cycles of 95uC for 15 s and 60uC
for 1 min. Results for target genes were normalized to GAPDH
expression. Fold increase in mRNA was calculated with the
22DDCT method.
Cell migration
A modified Boyden chamber (48-multiwell plates; Neuroprobe,
Gaithersburg, MD, USA) was used for chemotaxis studies [20].
Polyvinyl-pyrrolidone-free polycarbonate filters, 8 mm pore size,
were coated with 100 mg/mL collagen type I and 10 mg/mL
fibronectin (BD Biosciences, Bedford, MA, USA). Conditioned
medium of mDCs or ccDCs was prepared from 16106/ml mDCs
or ccDCs/mL cultured in RPMI-1640 containing 10% FBS for 2
days. The supernatants were collected, cleared of cells and debris
by centrifugation at 550 g for 5 min, aliquoted and stored at
-20uC until use. Some experiments were performed with media
recovered from mDCs and co-cultures grown in FBS-free
medium, in order to assess the influence of serum on cell
migration. Conditioned medium was added to the lower wells,
while cells (126103) in 50 L medium with 1% FBS were seeded
into the upper wells of the chamber, which was incubated at 37uC
for 6 h. Methanol-fixed cells were stained with Diff-Quik (Dade
Behring, Dudingen, CH) and cell migration was measured by
microscopic evaluation of the number of cells moved across the
filter, in ten randomly selected fields at magnification 400x. Each
experimental point was measured in triplicate. In neutralizing
experiments, CASMCs were let to migrate towards medium
conditioned by ccDCs in the presence of the neutralizing
monoclonal antibodies against IL-6, MCP-1 and TNFaa men-
tioned above for adhesion assay. For statistical analysis each well
was assumed as a sample unit. The data were normalized for each
experiment by expressing the number of migrating cells as per cent
of the average value in the corresponding unstimulated wells.
Since the results were distributed approximately symmetrically,
they were subjected to statistical analysis without further
transformation.
Multiplex assay
Supernatants of iDCs, mDCs, ccDCs and CASMCs were
recovered, centrifuged at 2500 rpm for 5 minutes and then
analyzed using Milliplex Map Kit technology (Merk-Millipore) on
BIOPLEX apparatus (Bio-Rad, Hercules, CA, USA) following
manufacturer’s recommendations, for the simultaneous quantifi-
cation of TNFa, IL-6, IL-1b, INFc, MCP-1. For mDCs and
ccDCs the supernatant was analysed upon 36 h culture or co-
culture respectively, i.e. upon DC maturation.
Adhesion assay
The adhesion of mature (mDCs) to CASMCs was analysed by
fluorescent assay using Vybrant Cell Adhesion Assay Kit
(Invitrogen, Carlsbad, CA, USA) [21]. Briefly, DCs were pulsed
with 5 mmol/L calcein and incubated 45 min with a monolayer of
CASMCs, which had been pre-treated for 12, 24 or 36 h with
TNFa or IFNc, either one 50ng/mL, in SmBM with 1% (v/v)
FBS but without growth factors. After washing, adherent cells
were counted with a Victor 3 fluorescence multireader (Perkin
Elmer) [21]. To assess the effect of neutralizing antibodies, DCs
were pre-treated with anti-CD18 (0.5 mg/well, BioLegend, San
Diego, CA, USA), anti-CD11c (0.5 mg/well, Millipore, Milan,
Dendritic Cells and Smooth Muscle Cell Interaction
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Italy), or anti-DC-SIGN (0.5 mg/well, R&D Systems) neutralizing
monoclonal antibodies or with non immune IgG2b and IgG1
(Merk-Millipore), for 1 h. To assess the effect of atorvastatin and
rosiglitazone on cell adhesion, CASMCs were pretreated with test
drugs and then stimulated with TNFa and IFNc for 24 h. After
24 h, CASMCs were washed twice and co-incubated for 45 min
with mDCs to assess cell adhesion.
Statistics
Data are reported as mean 6 standard error (SE). Differences
between two groups were determined by Student’s t test for
unpaired data. Differences between multiple groups were deter-
mined by ANOVA followed by Tukey’s multiple comparison test.
P values ,0.05 were recorded and considered as significant. In
experiments on cell migration, the correlation between variables
was evaluated by Spearman’s r test. The program Prism 5.0
(GraphPad Software, La Jolla, CA, USA) was used for all statistical
analyses.
Results
Coronary artery SMCs stimulate the maturation of iDCs
phenotype and function
After 36 h of co-culture with untreated CASMCs, iDCs
significantly increased the expression of HLA-DR, the maturation
markers CD83, CD38, CCR-7 and the co-stimulatory markers
CD80 and CD86, indicating that they had undergone maturation
(Fig.1 A and Fig. S1), similar to that achieved in DCs stimulated
with cytokines (mDCs) which represented the positive control. Pre-
treatment of CASMCs with IFNcand TNFa (50 ng/mL) for 24 h
did not further increase the expression of co-stimulatory molecules
and maturation markers by DCs. In order to evaluate the possible
contribution of serum to DC maturation, new experiments were
performed by setting co-cultures in RPMI medium in absence of
FBS. After 36 h co-culture, flow cytometry analysis demonstrated
increased expression of DC maturation markers similar to that
obtained with co-culture in the presence of serum, despite an
increase in cell death rate (9,5361,3%. and 5,661,9 in the
absence and in the presence of serum, respectively; Fig. S2).
In MLR, as expected, iDCs stimulated lymphocyte proliferation
slightly (Fig. 1B). When they were co-cultured with CASMCs a
significant increase occurred in the capacity to stimulate lympho-
cyte proliferation, comparable to that of mDCs; pre-treatment of
CASMCs with TNFa or IFNc did not further increase the
lymphocyte stimulating activity of ccDCs.
Cytokines and chemokines possibly relevant to CASMC/DC
interaction were measured in the supernatants of cell cultures. The
results indicate that CASMCs produced quite high concentrations
of IL-6 and high concentrations of MCP-1 in the absence of any
stimulation (Fig. 1C). mDC also produced high concentrations of
MCP-1. Co-culture of DCs and CASMC did not induce higher
production of MCP-1 and IL-6 compared to CASMCs alone.
Higher concentrations of TNFa´ were found in ccDC cultures
compared to CASMCs alone, but these concentrations were
similar to those secreted by immature DCs. IL-1aˆ was produced at
very low concentration by both iDCs and CASMCs, and the
concentration did not increase significantly in co-cultures. Since
TNFa´, IL-6 and IL-1 were used to mature iDCs to mDCs, their
concentrations in the medium of mDCs were not measured, in
order to avoid possible misinterpretation. A positivity for IFNa˜ was
seen only in the positive control, but in none of the experimental
cultures (data not shown). Given the anti-inflammatory properties
of HMG-CoA reductase inhibitors [22] and of PPARc agonists
[23], their effect on cytokine release from co-cultures was
measured: neither atorvastatin nor rosiglitazone influenced the
release of cytokines in co-cultures (Fig. 1C).
In order to verify that cytokines released from the co-cultures
were involved in DC maturation, blocking experiments were
performed. The presence of monoclonal neutralizing antibodies
against MCP-1 and TNFa´ partially inhibited iDC maturation,
while the neutralizing IL-6 antibody had no significant effect
(Fig. 1D). The observed inhibition was particularly evident for the
maturation marker CD83, for which the mean fluorescence
intensity (MFI) was 4.660.16, 4.560.17, 3.360.5, 3.460.51 and
3.460.16 for ccDCs, ccDCs plus anti-IL-6, ccDCs plus anti-
TNFa´, ccDCs plus anti-MCP-1 and ccDCs plus cocktail of
antibodies, respectively (n = 3; p,0.05 by ANOVA). Non-immune
IgG were ineffective (data not shown).
At electron microscopy, both mDCs and ccDCs were charac-
terized by well developed smooth endoplasmic reticulum and
Golgi apparatus, a few multivesicular bodies, and several
lysosomes, most of which were small and with homogenous
content (Fig. 2 A–D), as typical of well differentiated DCs. By
immunocytochemistry it was shown that iDC expressed DC-SIGN
faintly and mDC expressed this antigen intensely (Fig. 2 E–H),
while neither iDCs nor mDCs expressed CD207/langerin (not
shown); hence the cells had features of connective tissue DCs. Flow
cytometry confirmed surface expression of DC-SIGN in iDCs,
which increased during their maturation in either mDCs or ccDCs
(Fig. 2 I).
Soluble factors released by DCs stimulate CASMC to
enhance migration
To test the hypothesis that DC/CASMC influence may be
reciprocal, CASMCs were let to migrate in response to medium
conditioned by mDCs or by ccDCs, in the absence of any DC.
The migration of CASMCs was significantly enhanced by
conditioned medium from either mDC or ccDC (Fig. 3A). Given
Table 1. Primers and conditions for real time-PCR.
RefSeq Description Sequence (59-.39) Band size
NM_001078 hVCAM-1, forward GGCAGGCTGTAAAAGAATTGCA bp 66
hVCAM-1, reverse TCATGGTCACAGAGCCACCTT
NM_000201.2 hICAM-1, forward CAGACAGTGACCATCTACAGCTT bp 102
hICAM-1, reverse TTCTGAGACCTCTGGCTTCGT
NM_002046.3 hGAPDH, forward Not provided by Applied Biosystems Bp 118
hGAPDH, reverse Not provided by Applied Biosystems
doi:10.1371/journal.pone.0099652.t001
Dendritic Cells and Smooth Muscle Cell Interaction
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e99652
Dendritic Cells and Smooth Muscle Cell Interaction
PLOS ONE | www.plosone.org 5 June 2014 | Volume 9 | Issue 6 | e99652
Figure 1. Immunophenotypical and functional maturation of DCs. A) Flow cytometry for DC markers in immature DCs (iDCs), DCs matured
with a standard protocol (mDCs), DCs co-cultured with CASMCs (ccDCs) and DC co-cultured with CASMC pre-treated with 50 ng/mL TNFa and IFNc
(ccDCs + cytokines); all co-cultures were inside transwells. Mean 6SE of median fluorescence intensity (MFI), n = 12; *P,0.05 vs. iDC, ANOVA. B)
Proliferation of lymphocyte alone (0) and in mixed reaction with iDCs, mDCs, ccDC or ccDCs + cytokines. Lymphocyte proliferation is expressed as
mean 6SE of counts-per-minute/well (cpm/well; 4 experiments, each in triplicate); *P,0.05 vs. iDCs, ANOVA. C) IL-6, MCP-1, IL-1b and TNFa release
from CASMC, iDCs, mDCs, ccDCs as assayed by Milliplex method. Atorvastatin (ator; 1 mmol/L) and rosiglitazone (rosig; 20 mmol/L) did not influence
the release of cytokines in co-cultures. The release of cytokines was measured from 16106 cells DCs and 56104 CASMCs. Results are expressed as pg/
mL. Mean 6SE of 4 experiments. *P,0.05 vs iDC, ANOVA. D) Flow cytometry analysis of DC maturation and of the effect of neutralizing antibodies
against TNFa, MCP-1 and IL-6 or of a cocktail of all those antibodies. Representative histograms of ccDCs in the absence (filled histogram) and in the
presence of antibodies (open histogram, black lines) are shown. The histogram for the isotype control is included (open histogram, faint line). The
effect of non immune IgG is not shown.
doi:10.1371/journal.pone.0099652.g001
Figure 2. Characterization of co-cultured DCs. A–D) Electron microscopy of DCs matured in transwell culture with CASMC (A, B) or with
cytokines (C, D). Asterisks indicate lysosomes; hashes indicate smooth endoplasmic reticulum; arrowheads indicate occasional lipid droplets. Bars
= 2 mm (A, C) or 0.5 mm (B, D). E–H) Phase contrast (E, G) and immunofluorescence microscopy (F, H) for DC-SIGN in immature (iDCs; E, F) and mature
DCs (mDCs; G, H). The exposure time was the same for both F and H photomicrographs, to show that the labelling of iDCs was lighter than that of
mDCs. Note the labelling on cell extensions, indicating membrane expression of the antigen. Bar = 30 mm. I) Flow cytometry for DC-SIGN expression
in iDCs, mDCs and ccDCs. One representative histograms out of 3 performed is shown. The isotype control is included (open histogram).
doi:10.1371/journal.pone.0099652.g002
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the release of cytokines by ccDCs reported above, the effect of
neutralizing monoclonal antibodies on CASMC migration was
also assessed (Fig. 3B). The migration process of CASMCs induced
by ccDC conditioned medium was significantly reduced by a
cocktail containing antibodies against all the relevant cytokines
(TNFa´, MCP-1, IL-6). A significant effect on the inhibition of
migration process was also detected using the neutralizing
antibody against TNFa and MCP-1 alone, while the neutralizing
IL-6 alone did not reach significance (Fig. 3B).
In order to evaluate the possible contribution of serum in the
medium, CASMCs were let to migrate in response to medium
conditioned by DCs (either ccDC or mDCs) grown in the absence
of serum. CASMCs were still able to migrate in response to
ccDCs- and mDCs-conditioned medium without FBS, although
less intensely than when conditioned medium contained serum
(Fig. 3C). Cell migration in response to medium conditioned by
ccDCs was inversely correlated with the mortality of DCs in co-
cultures without serum (Fig. S3).
DCs adhere to CASMCs and binding is stimulated by an
inflammatory microenvironment
Untreated CASMCs bound human mDCs after 45 min
incubation. Pre-treatment of CASMCs with TNFa or IFNc
(50 ng/mL) for 12, 24 and 36 h significantly increased mDCs
adhesion to CASMCs (Fig. 4A). The maximal effect was obtained
with 24 h pre-treatment. The DCs adhering to CASMCs
contacted the latter cells through their dendrites, with small areas
of close approach (<20 nm) between membranes (Fig. 4B and C).
Adhesion between DCs and VSMCs with secretory phenotype
was demonstrated also in vivo, in a model of carotid injury in the rat
at all follow-up time points, i.e. 7, 14 and 21 days after injury
(Fig. 4D-G). DCs were identified as endowed with cytoplasmic
projections, variably rich in smooth vesicles and tubules,
multivesicular bodies and intermediate filaments, and poor in
lysosomes. Cells of smooth muscle lineage were identified as rich in
microfilament bundles; they showed either a secretory or a
contractile phenotype depending on whether microfilaments
occupied less or more than half the cytoplasm.
In order to investigate the molecular mechanisms of adhesion
between DCs and VSMCs in an inflammatory setting, we first
studied the expression of ICAM-1 and VCAM-1 gene in CASMCs
treated with TNFa or IFNc by real-time PCR. Figure 5A shows
that TNFa induced a significant increase of ICAM-1 and VCAM-
1 mRNA expression by CASMCs, with maximal effects after 24 h
stimulation. At the same experimental time point (24 h stimula-
tion), IFNc also significantly increased CASMC expression of
ICAM-1 and VCAM-1 genes but to a lesser extent than that
observed in response to TNFa. To confirm the involvement of
VCAM-1 and ICAM-1 in CASMC/DC interaction we pre-
treated mDC for 1 h with monoclonal neutralizing antibodies
against CD11c and CD18, which are the counter-receptors of
ICAM-1 and VCAM-1, and evaluated adhesion to CASMCs in
comparison with that of DCs pre-treated with irrelevant IgG.
Figs. 5B and 5C show that pre-treatment of DCs with anti CD11c
or anti CD18 neutralizing antibodies significantly reduced their
adhesion to CASMCs activated by either TNFa or IFNc Given
the expression of DC-SIGN by DCs and its proposed role in
adhesion to endothelial cells, we also assessed the effect of a
neutralizing antibody against DC-SIGN on mDC adhesion to
CASMCs: this antibody proved ineffective at any concentration
used (Fig. 5D).
Figure 3. Influence of DCs on CASMC migration. A) Effect of DC
conditioned media on CASMC migration. CASMCs were let to migrate in
medium conditioned by mature DCs (mDCs) or by co-cultured DCs
(ccDCs). Migration is expressed as percent increase over spontaneous
migration of untreated CASMCs (control). Mean 6SE of 4 experiments,
each in triplicate. *P,0.05 vs. control CASMCs, Student’s t test. B)
CASMC migration in response to medium conditioned by co-cultured
DCs (ccDCs) in the absence or in the presence of neutralizing
monoclonal antibodies against IL-6, (mAb-IL6, 1 mg/mL) TNFa (mAb-
TNFa, 1 mg/mL), MCP-1 (mAb-MCP1, 2 mg/mL) or all antibodies together
(mAb-cocktail). Migration is expressed as percent increase over
untreated CASMCs (control). Mean 6SD of 3 experiments, each in
triplicate. 1P,0.001 vs. ccDCs, ANOVA. C) Effect of DC conditioned
medium with or without FBS on CASMC migration. Migration is
expressed as percent increase over spontaneous migration of untreated
CASMCs (control). Mean 6SE (N= 16), each in triplicate. 1P,0.001 vs
unstimulated cells (control); #P,0.01 vs serum-free medium (-FBS)
(ANOVA).
doi:10.1371/journal.pone.0099652.g003
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The adhesion between mDC and CASMC is responsive to
drugs
The effect of atorvastatin and rosiglitazone was assessed on DC-
CASMC adhesion by pre-treating CASMCs with atorvastatin
(0.01–1 mM) or rosiglitazone (1–20 mM) for 1 h and then
stimulating them with IFNc or TNFa for 24 h before measuring
adhesion to DCs. Adhesion was concentration-dependently
inhibited by either atorvastatin (Fig. 6A) or rosiglitazone pre-
treatment (Fig. 6B). The maximal effect was obtained with 1 mM
atorvastatin and with 20 mM rosiglitazone, which nearly prevented
the adhesion between the two cell types (Fig. 6). These highest
concentrations used were devoid of any toxic effect on CASMCs,
as revealed by trypan blue exclusion (data not shown). The
dependence of atorvastatin effect on HMGCoA-reductase inhibi-
tion was confirmed by the addition of 300 mM mevalonate, which
entirely prevented the inhibition of cell adhesion (Fig. 6A).
Discussion
We have obtained evidence that interaction between human
DCs and coronary smooth muscle cells (CASMCs) stimulates both
the transition of human iDCs to a mature, efficiently immunos-
timulatory phenotype and the migration of CASMCs; reciprocal
influence is exerted through soluble factors, which include MCP-1
and TNFa. The results upon co-colture in the absence of serum
confirmed this reciprocal stimulation. We could also show that
these cells adhere to each other with the intermediation of ICAM-
1, VCAM-1 and their counter-receptor CD11c/CD18. An
inflammatory setting, such as that represented by the addition of
TNFa and IFNc, stimulates DC adhesion to CASMCs. Factors
released from mature DCs promote CASMC migration, while
both the HMG-CoA reductase inhibitor atorvastatin and the
PPARc agonist rosiglitazone - known to have anti-inflammatory
effects - counteract the cytokine-stimulated adhesion.
Adhesion between DCs and VSMCs could be replicated in vivo
upon carotid injury in the rat; this experimental animal model, as
previously demonstrated by Rinaldi et al. [23], is characterized by
a significant inflammatory process. To the best of our knowledge,
Figure 4. Adhesion of mDC to vascular smooth muscle cells. A) Human mature calcein-labeled DC adhesion to CASMC pre-treated for 12-36 h
with 50 ng/mL IFNc or with 50 ng/mL TNFa. After washing, a suspension of calcein-labeled DCs was added and let to adhere for 45 m. Mean 6SE of
6 experiments, each in triplicate. Results are expressed as percentage of mDC adhesion over that on untreated CASMCs (control). *P,0.05, ANOVA. B,
C) Electron microscopy of mDCs adherent to citokyne-treated CASMCs; SMC: smooth muscle cells. Bars = 4 mm (B), or 0.5 mm (C). D-G) Electron
microscopy of rat carotid repair tissue (neointima) at 7 (D, E), 14 (F) and 21 d (G) upon crush and incision injury; panel H is an enlargement of the
boxed part of panel G. Dendritic cells (D) are seen in contact with smooth muscle cells with secretory phenotype (asterisks). Bar = 2 mm (D), 500 nm
(E), or 1 mm (F, G).
doi:10.1371/journal.pone.0099652.g004
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the present data are the first to demonstrate that DCs and
CASMCs can stimulate each other by releasing soluble factors,
hence they may cooperate in driving inflammation within the
vascular wall, and that atorvastatin and rosiglitazone can interfere
in such stimulation.
Few studies have investigated the involvement of DCs in
vascular inflammation and remodelling. Feng et al.[24] demon-
strated that ETS-1 transcription factor mediates inflammation and
neointima formation in a model of carotid artery balloon injury,
however they did not specifically addressed the behaviour and
possible role of DCs even if it is known that ETS-1 is involved in
DC adhesion [25].
Dendritic cells are specialized in antigen presentation and may
also regulate inflammatory processes independent of immune
mechanisms by stimulating the recruitment of neutrophils and NK
cells and by secreting type I IFN [4,26,27]. Under physiological
conditions the wall of human arterial branches down to at least 3–
5 mm diameter hosts iDCs [6] - derived from circulating
precursors - in the adventitia and among VSMCs where they
are supposed to take care of surveillance against antigens as
vascular-associated lymphoid tissue. DCs co-localize with neoin-
timal VSMCs, besides T-cells, in human atherosclerotic lesions
[6,9] and in the rat carotid reacting to experimental injury (present
data). Our data indicate that the co-localization is not a mere issue
of tissue geometry, because they demonstrate that soluble factors
released by CASMCs in the presence of iDC stimulate the latter
towards a mature phenotype (mDCs), virtually identical to that
achieved with a standard protocol and capable of stimulating
allogeneic lymphocyte proliferation. Moreover, maturation of DCs
was achieved independent of the presence of serum in the
medium.
Among the soluble factors possibly responsible for DC/CASMC
interaction, we paid attention to IL-1b, IL-6, IFNc, TNFa and
MCP-1, for several reasons. IL-1b can stimulate DC maturation
[17,28], is expressed in human and animal atherosclerotic lesions
and has been demonstrated to stimulate VSMC migration [29].
IFNc is found in human atherosclerotic lesions, stimulates VSMC
adhesion molecule expression [30] and CASMC adhesiveness
(present data). IL-6 is a biomarker of inflammation in cardiovas-
cular diseases and stimulates maturation of iDCs [28,30]. MCP-1
is a CC-chemokine secreted by vascular wall cells, which is
involved in vascular wall remodelling [29,31,32] and in the
maturation of DCs [33]. Our data show that IL-6 and MCP-1 are
produced at quite high concentrations by CASMCs even alone,
but at much lower concentration by iDCs. On the contrary, mDCs
express huge amount of MCP-1 which in turn may mediate
CASMC activation. TNFa too may play some role in CASMC
stimulation, although its concentration in the medium of mDCs
cannot be unequivocally interpreted since it is used to mature
iDCs to mDCs. IL-1b was produced at very low concentration by
both iDCs and CASMCs and the concentration did not increase
significantly in co-cultures, so we would not propose a role for this
cytokine in mediating intercellular influence. We confirmed an
influence of CASMCs on iDC maturation with blocking exper-
Figure 5. Adhesion molecules and counter-receptors involved in cytokine-induced mDC adhesion to CASMCs. A) real time RT-PCR of
ICAM-1 or VCAM-1 mRNA expression by CASMCs stimulated with TNFa or INFc (50 ng/mL each cytokine) for 24 h. Data are expressed as fold increase
over unstimulated CASMCs. Mean 6SE of 3 experiments. *P,0.05, ***P,0.001 vs. untreated CASMCs, Student’s t test. B–D) Effect of neutralizing
antibodies on mDC adhesion to CASMCs. CASMCs were untreated (0) or pre-treated with: B) anti-CD11c (0.5 mg/well), C) anti-CD18 (0.5 mg/well), or D)
anti-DC-SIGN (0.5 mg/well) neutralizing antibodies. They were pretreated with IFNc or TNFa for 24 h and then washed before the assay. NI-IgG: non
immune IgG. Mean 6SE of 5-7 experiments, each in triplicate. *P,0.05 vs. respective control, Student’s t test.
doi:10.1371/journal.pone.0099652.g005
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iments, which showed a decreased expression of CD83, CD80 and
CD86 in co-cultured DCs (ccDCs) treated with neutralizing
antibodies against MCP-1 and TNFa. Dendritic cells, either
immature and mature, express chemokine receptors which are
critical for their migration and maturation [33,34,35]. Our present
data lend support to MCP-1 playing the latter role and to the
interaction between DCs and VSMCs driving vascular inflamma-
tion.
No significant inhibition of DC maturation was observed in the
presence of neutralizing antibody against IL-6, although it is
known that IL-6 can stimulate DC maturation [28]. This result
may be explained by the fact that in the co-culture medium there
were other cytokines and chemokines together with IL6, in
particular MCP-1 and TNFa (Figure 1C), which could be
sufficient to cause DC maturation even when IL-6 effect was
prevented.
Present data also demonstrate an enhanced DC adhesion to
cytokine-pre-treated CASMCs, which appeared mediated by
synthesis of ICAM-1 and VCAM-1 by CASMCs since the
mRNAs for these molecules were increased upon culture with
cytokines and, conversely, antibodies neutralizing their counter-
receptors CD11c and CD18 significantly inhibited the event.
Adhesion to cytokine-untreated CASMCs was not significantly
affected by the antibodies, indicating that there are also other
receptor-counter-receptors couples at work in basal conditions. It
had already been demonstrated that VSMCs contribute to the
retention of monocytes and neutrophils in the arterial wall [36],
and previous studies had demonstrated an up-regulation of ICAM-
1 and VCAM-1 mRNAs on intimal and media VSMCs of
atherosclerotic vessels [37] and on isolated human smooth muscle
cells [38,39]. The present data point to TNFa and IFNc as
stimulating that up-regulation. We propose that VSMCs are
implicated in the localization of DCs in the arterial wall (and not
Figure 6. Effects of atorvastatin and rosiglitazone on mDC adhesion to cytokine-stimulated CASMCs. CASMCs were pre-treated with (A)
atorvastatin (0.01–1 mmol/L) or (B) rosiglitazone (1–20 mmol/L) before stimulation with 50 ng/mL TNFa or IFNc for 24 h followed by assay of DC
adhesion as indicated for Figure 4. Mevalonate (300 mM), added to the maximal atorvastatin concentration, reverted statin effect (A). Adhesion is
reported as percent of that induced by TNFa or IFNc (control). Mean 6SE of 6–8 experiments, each in triplicate. *P,0.05 vs. control, ANOVA. (C)
Representative experiment of DC to CASMC adhesion. Calcein-labelled mDC were incubated for 45 min with control CASMCs (0) or with CASMCs
stimulated with TNFa or IFNc (50 ng/mL either cytokine) and pre-treated, or not pre-treated, with 1 mmol/L atorvastatin (atorv) or 20 mmol/L
rosiglitazone (rosigl). Mevalonate (300 mmol/L) was used to confirm atorvastatin selectivity.
doi:10.1371/journal.pone.0099652.g006
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only of their monocyte precursors) and that ICAM-1 and VCAM-
1 and their counter-receptors play roles in that localization.
Afterwards, the interaction of VSMCs with DCs can concur to the
final maturation and functional activation of the latter cells.
Therefore we propose a role for that interaction in perpetuating
and worsening the inflammatory condition leading to the
progression and complication of atheroma and to vascular
remodelling. It has been previously demonstrated that diabetes-
like conditions stimulates VSMCs to bind human and mouse
monocytic leukemia cells and to promote their differentiation to
macrophages [40]. Also, DCs obtained from obese and diabetic
(T2D) patients significantly increase their adhesion to CASMCs,
compared to DCs isolated from either obese, non-diabetic patients
or healthy subjects [21]. Since diabetes is a well known
atherogenic disease involving - among others - inflammatory
mechanisms, we propose that these mechanisms concur to activate
DC-VSMC interactions and reciprocal activation also in vivo, as a
step of the vicious cycle leading to atheroma progression and
complication.
Dendritic cells present in an inflamed tissue also stimulate
lymphocytes and other leukocytes to secrete pleiotropic molecules
and the response of VSMC in vivo depends on all the stimuli they
receive together. The present findings indicate that these stimuli
include some ones directly given by DCs. These cells therefore are
far more reaching than antigen presentation to lymphocytes, since
they directly influence VSMC activation, which - at the best of our
knowledge - is an original finding. Migration of CASMCs in
response to medium conditioned by ccDCs or by mDCs in the
absence of serum was less intensely stimulated than when the
conditioned media were produced in the presence of serum. This
may be due to less effective secretion of stimulating factors by DCs
differentiated in the absence of serum, concomitant with the
higher mortality of DCs in this condition.
A great number of studies performed also in patients [41] have
shown that HMG-CoA-reductase inhibitors limit the progression
of atherosclerosis and may even induce its regression and that
glitazones are anti-inflammatory and anti-atherogenic agents
besides anti-diabetic [42]. Several diverse mechanisms are at play,
however their main consequence is a reduction in inflammation
[22,41,42]. In the present paper we could demonstrate that pre-
treatment of CASMCs with atorvastatin (0.01–1 mmol/L) or
rosiglitazone (1–20 mmol/L) significantly impairs the enhance-
ment of mDC adhesion to CASMCs in response to inflammatory
cytokines. Given the pleiotropic and anti-inflammatory effect of
statins [22,43–45] and PPARc agonists [23], we assessed whether
these drugs influenced also the release of cytokines in co-cultures.
This did not happen, so the effect on cell adhesion may be a direct
one. Previous in vitro experiments had demonstrated that statins
suppress a range of DC functions [46] and adhesion to VSMC
should be added to the list. This may at least in part explain the
finding that statin administration lowers DC number in athero-
sclerotic plaques [47]. Rosiglitazone hampers the formation of a
neo-intima in the injured rat carotid [23] and another thiazoli-
dinedione, ciglitazone, is able to impair oxLDL-induced DC
maturation and function [48]; these effects of glitazones seem
independent of those on glycaemia and may hint to a relevant role
of PPARc in atheroma formation and progression.
We are aware of the limitations of the in vitro model used here.
However, no available model - as far as we know - allows to dissect
the behaviour of neointimal smooth muscle cells from those of the
intima, nor to have in culture high enough numbers of freshly
isolated vascular smooth muscle cells for experiments in order to
circumvent the possible effects of multiple passages in vitro.
Therefore, we believe that the information gained from the
present investigation may be helpful to better understand the cell
interactions and the regulatory mechanisms during vascular injury
response and should like to draw attention on what we feel as the
two main original findings of this study: (1) co-localization of DCs
and VSCMCs in atherosclerosis and upon injury not only can play
a role in the retention of DCs in the tissue (as indicated by previous
studies) but induce both the maturation of DCs and the migration
of VSMCs; (2) an inflammatory microenvironment promotes
adhesion between the two cell types. Therefore DC-VSMC
interaction appears as a relevant link in the chain of events leading
to complications of atherosclerosis and vascular surgery. Other
points, as underscored above, are: (3) the addition of VSMCs to
the cohort of cells directly responsive to DCs; (4) the identification
of some putative molecular intermediates of the interaction, i.e.
ICAM-1 and VCAM-1 among cell adhesion molecules and TNFa
and MCP-1 among soluble factors; and (5) the finding that anti-
inflammatory drugs endowed with an anti-atherogenic properties
may play the latter role also through inhibition of DC-VSMC
interaction.
Supporting Information
Figure S1 Flow cytometry analysis of co-cultured DCs.
Representative plots of cell surface antigens (filled histograms)
expressed by human immature dendritic cells (iDCs), monocyte
derived dendritic cells matured with cytokines (mDCs), and
dendritic cells matured upon co-culture with human coronary
artery smooth muscle cells in transwell inserts, without addition of
standard cocktail of cytokines (ccDCs). The open histograms show
the results with the isotype controls. In this experiment, dendritic
cells ccDCs showed increased expression of CD80, CD83, CD86,
CD38 and CCR-7 and HLA-DR similar to mDCs, which was not
further increased by the addition of cytokines during co-culture
(ccDCs+cytok).
(TIF)
Figure S2 Flow cytometry analysis of co-cultured DCs
in absence of serum. Flow cytometry analysis of DC marker
expression in DCs co-cultured for 36 h in absence (ccDCs – FBS)
and in the presence (ccDCs + FBS) of serum. Mean fluorescence
intensity (MFI) was calculated in gated cells excluding dead ones,
i.e. excluding those positive for 7-AAD. Mean 6SE, n= 6.
(TIF)
Figure S3 CASMC migration in response to medium
conditioned by DCs. DCs were co-cultured with CASMCs for
36 h in serum-free RPMI. DC death, as measured by flow
cytometry, resulted on the average 9,5361,3%. A) CASMC
migration in response to medium conditioned by ccDCs with
higher (.10%; N=8) or lower (,10%; N=8) death rate. Mean
6SE; *P,0.05 vs medium conditioned by ccDCs with death rate
.10%, Student’s t test. B) Correlation between CASMC
migration and percentage of DC death rate. Spearman’s rank
correlation coefficient (r) was -0.4929, p,0.05 vs. r=0.
(TIF)
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